This company has no active jobs


Biomics Biopharma Limited (the Company) is the ultimate parent company of the Biomics Group. The Company’s wholly owned subsidiary, Biomics Biotechnologies Co., Ltd (Biomics), was incorporated in 2006 in the People’s Republic of China (PRC). Biomics is a near-clinical-stage biopharmaceutical company in developing and commercialising double stranded ribonucleic acid (dsRNA) based innovative products for unmet medical needs. As early as the early-mid 2000s, the Company’s scientific founders were leaders in the field of small interfering RNA (siRNA) library construction, drug delivery and liposome formulation and production in USA. In 2012, the world’s first RNAi-based marketed product, Britena for skin depigmentation, was launched by Genecon Biotechnologies Co., Ltd., a joint venture company in which Biomics then had a 49% interest. In 2015, the Group launched its first RNAi-based skincare product, CoSensia, for acne. Since its establishment the Group has invested over $11 million in research and development. The Company believes that now is the appropriate time to maximise the CoSensia opportunity in China and globally, and at the same time advance its Hepatitis B virus (HBV) therapeutic program to the clinical proof of concept stage.
  • Company Phone 08 9486 4036
  • Address Line 1 Level 36, Gateway Tower, 1 Macquarie Place, SYDNEY, NSW, AUSTRALIA,
  • City Sydney
  • State New South Wales
  • Country Australia
  • Postcode 2000
  • Industry Class Pend
Connect with us

Hi! How can we help you?

Click below button to start chat

Chat Icon
chat icon